| Company Name: |
Shanghai Hongye Biotechnology Co. Ltd
|
| Tel: |
400-9205774 |
| Email: |
sales@glpbio.cn |
| Products Intro: |
Product Name:CCG-232601
CAS:1922099-21-5
Purity:>98% Package:1mg;10mg;50mg;100mg;
|
| Company Name: |
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
|
| Tel: |
18818260767 |
| Email: |
sales@chemegen.com |
| Products Intro: |
Product Name:CCG-232601
CAS:1922099-21-5
Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
CCG-232601 manufacturers
- CCG-232601
-
-
2025-12-22
- CAS:1922099-21-5
- Purity:
- Supply Ability: 10g
|
| | CCG-232601 Basic information |
| Product Name: | CCG-232601 | | Synonyms: | CCG-232601;CCG-232601
(CCG232601);3-Piperidinecarboxamide, N-(4-chlorophenyl)-5,5-difluoro-1-[3-(4-pyridinyl)benzoyl]-;N-(4-chlorophenyl)-5,5-difluoro-1-[3-(4-pyridinyl)benzoyl]-3-piperidinecarboxamide;N-(4-Chlorophenyl)-5,5-difluoro-1-(3-(pyridin-4-yl)benzoyl)piperidine-3-carboxamide | | CAS: | 1922099-21-5 | | MF: | C24H20ClF2N3O2 | | MW: | 455.88 | | EINECS: | | | Product Categories: | | | Mol File: | 1922099-21-5.mol |  |
| | CCG-232601 Chemical Properties |
| Boiling point | 683.1±55.0 °C(Predicted) | | density | 1.39±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2) (1:3): 0.25 mg/ml | | form | A crystalline solid | | pka | 13.69±0.70(Predicted) | | color | White to off-white |
| | CCG-232601 Usage And Synthesis |
| Description | CCG-232601 is an inhibitor of the Rho/MRTF/SRF transcriptional pathway and a derivative of CCG-203971 . CCG-232601 inhibits MRTF-dependent transcription in HEK293T cells (IC50 = 0.55 μM in a luciferase reporter assay). It also reduces expression of α-smooth muscle actin (α-SMA) in TGF-β-stimulated human dermal fibroblasts to 31% of control when used at a concentration of 10 μM. CCG-232601 (50 mg/kg) inhibits increases in dermal thickness and hydroxyproline content in a mouse model of dermal fibrosis induced by bleomycin . | | Uses | CCG-232601 (compound 8f) is a potent and orally active Rho/MRTF/SRF transcriptional pathway inhibitor. CCG-232601 inhibits the development of Bleomycin-induced dermal fibrosis in mice. CCG-232601 has the potential for the research of antifibrotic for systemic scleroderma[1]. | | in vivo | CCG-232601 (50 mg/kg; i.g.; intracutaneous injections of bleomycin; daily for 14 days) inhibits bleomycin-induced skin fibrosis in mice[1]. | | References | [1] Hutchings KM, et al. Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. Bioorg Med Chem Lett. 2017 Apr 15;27(8):1744-1749. DOI:10.1016/j.bmcl.2017.02.070 |
| | CCG-232601 Preparation Products And Raw materials |
|